Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Stock Chart & Stats
$18.39
-$0.12(-0.77%)
At close: 4:00 PM EST
$18.39
-$0.12(-0.77%)
Day’s Range― - ―
52-Week Range$6.78 - $23.56
Previous CloseN/A
Volume385.49K
Average Volume (3M)2.51M
Market Cap
$2.35B
Enterprise Value$2.03B
Total Cash (Recent Filing)$523.41M
Total Debt (Recent Filing)$157.74M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding117,673,386
10 Day Avg. Volume2,338,405
30 Day Avg. Volume2,508,096
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda-162.22
Forecast
1Y Price Target
$20.08Price Target Upside9.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$612.26M
Bulls Say, Bears Say
Bulls Say
Consumables GrowthRobust growth in spatial consumables and customers running more complex experiments underpins recurring revenue and helps improve gross margins as utilization rises.
Product AdoptionStrong adoption of the Flex Apex assay together with rising Xenium utilization indicates customers are embracing new platforms, supporting future demand for instruments and related consumables.
Research Funding And PolicyGreater clarity on public research budgets and rules for indirect funding reduces downside risk to academic and government lab spending, improving revenue visibility.
Bears Say
Guidance And Visibility RiskWith limited forward guidance and some results aided by shifted orders, meaningful stock upside will likely require clear upward revisions to revenue forecasts to restore confidence.
Lab Budget ConstraintsConstrained lab budgets and deliberate customer purchasing behavior could limit instrument placements and keep near-term revenue growth muted.
Pricing Pressure And Product MixPricing pressure from lower-priced offerings and an unfavorable product mix may offset volume gains and compress consumables revenue per experiment.
10x Genomics News
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $6.78 and its highest was $23.56 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $2.35B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is May 06, 2026 which is in 43 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Feb 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.203 by $0.073.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.27.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 117,673,386 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.203. Following the earnings report the stock price went up 3.484%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.08 (9.19% Upside)
$20.08 (9.19% Upside)
Blogger Sentiment
Neutral
TXG Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $490.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.82%
12-Months-Change
Fundamentals
Return on Equity
-5.69%
Trailing 12-Months
Asset Growth
13.36%
Trailing 12-Months
Company Description
10x Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
TXG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong operational and commercial progress in consumables, reaction volumes, product innovation (notably FLEX APEX and Xenium), improved gross margin, and a materially stronger cash position were clear positives. Offsetting these wins were meaningful declines in instrument revenue, continued capital expenditure constraints, regional funding variability (notably the Americas), and pricing/mix considerations from lower-cost assays. Management reinstated cautious but constructive guidance for 2026 (flat-to-modest growth excluding settlements) and emphasized continued cost discipline.View all TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$20.08
▲(9.19% Upside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.52% Insiders
24.82% Mutual Funds
34.10% Other Institutional Investors
12.85% Public Companies and
Individual Investors